Q-omics provides the consensus-scored KRT74 profile across patient tissues and cancer cell-line models. KRT74 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, KRT74 is differentially expressed in 9, with the highest sampling consensus in LUSC. Additionally, KRT74 RNA expression shows 9,673 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight COAD, LUSC, and ESCA as cancer lineages where KRT74 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KRT74 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KRT74 survival associations across molecular data types. KRT74 RNA expression shows survival associations in the most cancer types (14), followed by mutation status (5) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KRT74 RNA expression–survival associations across cancer types. High KRT74 expression shows unfavorable associations in COAD, SKCM and LUAD, but favorable associations in LUSC, CESC and STAD. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for KRT74 RNA expression.
This table summarizes KRT74 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 3. The strongest signals are observed in LUSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for KRT74. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KRT74 shows lower tumor expression in BRCA and LIHC and higher tumor expression in LUSC, BLCA, COAD and HNSC. The LUSC box plot shows higher KRT74 RNA expression in tumor versus normal tissue (log2 FC = +1.008, t-test p < 0.001).
This table shows molecular features associated with KRT74 in patient tissues and cancer cell lines. In patient samples, KRT74 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set. In cancer cell lines, KRT74 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in BREAST and LARGE_INTESTINE.
